[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sohag University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":583},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,400,0,25,[9,51,79,105,132,151,173,196,215,242,267,285,306,327,347,365,382,406,425,450,468,491,517,534,557],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652934","genetic-study-of-otof--related-auditory-neuropathy-spectrum-disorder-100652934",false,"NCT07778641","Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder","Inclusion Criteria:\n\n1. The study will be including 30 subjects of 30 patients of both sexes of any age with congenital hearing loss and confirmed diagnosis of non-syndromic ANSD:\n\n   A) Disproportionate speech discrimination score (SDS) with the hearing threshold level.\n\n   B)The auditory brainstem response (ABR) test with no waveform, disturbed waves, nor detectable wave V at high intense stimulus.\n\n   C) The otoacoustic emission (OAE) and\u002For cochlear microphonic (CM) potential may be present.\n2. Informed consent.\n\nExclusion Criteria:\n\n* 1\\) Known acquired risk factors of ANSD as preterm, hypoxia, hyperbilirubinemia. 2) Conductive hearing loss. 3) Syndromic ANSD hearing loss. 3) Binaural cochlear implants. 4) Inner ear malformation, cochlear nerve aplasia or hypoplasia.","ALL",{"count":18,"type":19},30,"ESTIMATED","3 Months","OBSERVATIONAL","The aim of this observational study is to determine the prevalence of OTOF gene variants among patients with auditory neuropathy spectrum disorder (ANSD). The primary research question is whether patients with ANSD carry a pathogenic or likely pathogenic OTOF gene variant. Participants will undergo genetic analysis of the OTOF gene.",[24,25],"Auditory Neuropathy Spectrum Disorder","Auditory Neuropathy",[27,28,29,30,31,32,33,34,35,36,37],"Otoferlin","Auditory neuropathy spectrum disorder","ANSD","Auditory synaptopathy","Genetic Testing","Whole Exome Sequencing","OTOF mutation","Hereditary hearing loss","Molecular testing","OTOF","OTOF Variants","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":19},"2026-08",{"date":46,"type":19},"2027-02",{"name":48,"class":49},"Sohag University","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":59,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100652266","role-of-kynurenine-pathway-and-its-metabolites-in-depressive-disorders-major-depressive-disorder-is-suspected-to-have-the-greatest-burden-by-2030kynurenine-pathway-is-major-route-through-which-the-essential-amino-acid-tryptophan-is-metabolised-and-activated-in-time-of-stress-and-immune-activation-100652266","NCT07771517","Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.","Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders","Inclusion Criteria:\n\n* age group 18: 60 years old\n* cases are drug free of at least 4 months\n\nExclusion Criteria:\n\n* patients with comorbid other psychiatric disorders( SUD,anxiety)\n* patients with IQ below 90\n* patients with psychotic features\n* patients with postpartum depression\n* patients with chronic medical illness that might affect immune function\n* patients under treatment with immune modulating therapy",true,"18 Years",{"count":61,"type":19},90,"This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits",[64],"Major Depressive Disorder (MDD)",[66,67,68,69,70,71],"Kynurenine pathway","MDD","Kynurenine pathway in depressive disorders","Depressive disorder","Bipolar disorder","Role of kynurenine pathway and its Metabolites in depressive disorders",{"date":73,"type":42},"2026-08-20",{"date":75,"type":19},"2027-03-14",{"date":77,"type":19},"2029-05-20",{"name":48,"class":49},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":86,"minAge":59,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100652729","evaluation-of-non-surgical-treatment-of-breast-abscess-100652729","NCT07777783","Evaluation of Non-Surgical Treatment of Breast Abscess","Evaluation of the Non-Surgical Treatment of Breast Abscess","Inclusion Criteria:\n\n* Adult female patients diagnosed with lactational and non-lactational breast abscesses on clinical and sonographic grounds.\n* Patients undergoing initial non-surgical treatment in the form of ultrasound-guided aspiration\u002Fre-aspiration with or without catheter drainage plus systemic antibiotics.\n\nExclusion Criteria:\n\n* Suspicion of inflammatory breast cancer or underlying breast malignancy.\n* Frank skin necrosis, thinning, or ruptured abscess overlying the affected breast.\n* Patients with breast implants in situ on the affected side.\n* History of breast surgery within 90 days of presentation.\n* Chronic or recurrent breast abscesses.","FEMALE",{"count":88,"type":19},50,"Breast abscess is a localized suppurative complication of breast infection commonly managed by ultrasound-guided needle aspiration combined with antibiotic therapy. This prospective observational study aims to evaluate the clinical outcomes and prognostic factors associated with successful non-surgical management versus treatment failure requiring surgical intervention in adult female patients with lactational and non-lactational breast abscesses.",[91],"Breast Abscess",[93,94,95,96],"Ultrasound-guided aspiration","Non-surgical treatment","Needle aspiration","Mastitis","RECRUITING","2026-08-17",{"date":73,"type":42},{"date":101,"type":42},"2026-06-01",{"date":103,"type":19},"2027-05",{"name":48,"class":49},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":50},"100652535","the-effect-of-an-integrated-mobile-health-platform-on-early-detection-of-clinical-outcomes-of-critical-ill-patients-100652535","NCT07773675","The Effect of an Integrated Mobile Health Platform on Early Detection of Clinical Outcomes of Critical Ill Patients","Inclusion Criteria:\n\n1. Adult patients aged 18-65 years.\n2. Anticipated ICU stay of more than 24 hours.\n3. Clinical requirement and ability to continuously monitor vital signs and urine output.\n4. Obtained written informed consent from the patient or their legal guardians.\n\nExclusion Criteria:\n\n1. Patients placed in strict isolation due to highly infectious diseases.\n2. Death within 24 hours of ICU admission.\n3. Patients transferred from another external Intensive Care Unit.\n4. Re-admission to the ICU during the active study period.\n5. Pre-existing chronic altered consciousness or irreversible neurological deficit.\n6. Patients who underwent pre-hospital cardiopulmonary resuscitation (CPR).","65 Years",{"count":113,"type":19},250,"INTERVENTIONAL",[116],"NA","This study will aim to examine the Effect of integrated Mobile Health Platform on early detection of clinical outcomes of Critical ill patients.",[119,120],"Mobile Health Platform","Clinical Outcomes",[122,123],"Mobile health platform","Early detection","2026-08-16",{"date":126,"type":42},"2026-08-19",{"date":128,"type":19},"2026-07-28",{"date":130,"type":19},"2027-05-28",{"name":48,"class":49},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":136,"conditions":140,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":50},"100652494","prognostic-value-enhancement-of-sequential-organ-failure-assessment-sofa-score-by-neutrophil-lymphocyte-ratio-and-red-cell-distribution-width-in-cardiogenic-shock-patients-100652494","NCT07773597","Prognostic Value Enhancement Of Sequential Organ Failure Assessment )SOFA( Score by Neutrophil-Lymphocyte Ratio and Red Cell Distribution Width in Cardiogenic Shock Patients.","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n\nDiagnosis of cardiogenic shock based on:\n\nSystolic blood pressure \\\u003C 90 mmHg for ≥30 minutes or need for vasopressor support Signs of tissue hypoperfusion (cold extremities, oliguria, altered mental status, elevated lactate) Evidence of cardiac dysfunction Cardiogenic shock secondary to acute coronary syndrome or other cardiac causes Availability of complete blood count on admission\n\nExclusion Criteria:\n\n* Septic, hypovolemic, or obstructive shock Active infection or chronic inflammatory disease Hematological disorders affecting leukocytes or red blood cells Malignancy Chronic liver disease Recent blood transfusion Patients on immunosuppressive or steroid therapy",{"count":139,"type":19},150,[141],"Cardiogenic Shock",[143],"Neutrophil-Lymphocyte Ratio and Red Cell Distribution Width in Cardiogenic Shock Patients.","2026-08-14",{"date":126,"type":42},{"date":147,"type":19},"2026-08-30",{"date":149,"type":19},"2027-01-31",{"name":48,"class":49},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":158,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":114,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":50},"100651881","transjugular-and-transfemoral-embolization-for-varicocele-100651881","NCT07764900","Transjugular and Transfemoral Embolization for Varicocele.","Combined Role of Transjugular and Transfemoral Embolization in the Management of Varicocele.","Inclusion Criteria:\n\n* 1\\. Male patients aged 16-60 years. 2. Clinically palpable varicocele (Grade II or III) or subclinical varicocele associated with abnormal semen parameters.\n\n  3\\. Recurrent varicocele following previous surgical treatment. 4. Presence of scrotal pain, testicular atrophy, or infertility attributed to varicocele.\n\n  5\\. Willingness to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n\\- 1. Secondary varicocele due to a retroperitoneal mass or renal vein obstruction.\n\n2\\. Known allergy to iodinated contrast media. 3. Coagulation disorders or contraindications to endovascular procedures.","MALE","16 Years","60 Years",{"count":18,"type":19},[116],"This prospective study will evaluate two different approaches for performing embolization to treat varicocele, a condition in which the veins around the testicle become enlarged. Thirty patients with varicocele will undergo embolization using either a transjugular approach, through a vein in the neck, or a transfemoral approach, through a vein in the groin. The choice of approach will depend on the patient's venous anatomy and the feasibility of the procedure. Patients will be followed up at one and three months after the procedure to assess treatment effectiveness, symptom improvement, and any complications.",[165],"Varicocele","2026-08-13",{"date":144,"type":42},{"date":169,"type":42},"2026-04-10",{"date":171,"type":19},"2027-05-10",{"name":48,"class":49},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":50},"100652133","ultrasound-biomicroscopic-assessment-of-intraocular-lens-tilt-and-decenteration-after-phacoemulsification-100652133","NCT07769944","Ultrasound Biomicroscopic Assessment of Intraocular Lens Tilt and Decenteration After Phacoemulsification","Inclusion Criteria:\n\n* Both sexes.\n* Patients with senile cataract prepared for phacoemulsification and IOL implantation.\n\nExclusion Criteria:\n\n* Age \\\u003C45 years.\n* Complicated ataract.\n* Coexisting ocular disorders (Glaucoma, Pseudoexfoliation Syndrome, Sublaxation, Chronic Iridocyclitis).\n* Previous ocular surgery.\n* Complicated phacoemulsification.","45 Years",{"count":181,"type":19},100,"This study aims to assess intraocular lens (IOL) tilt and decenteration by means of ultrasound biomicroscopy after phacoemulsification.",[184,185,186,187,188],"Ultrasound Biomicroscopy","Intraocular Lens","Tilt","Decenteration","Phacoemulsification","2026-08-12",{"date":39,"type":42},{"date":192,"type":42},"2025-10-01",{"date":194,"type":19},"2026-10-01",{"name":48,"class":49},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":205,"studyType":21,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":50},"100652072","clinical-characteristics-and-prognostic-factors-in-patients-with-meningitis-at-sohag-governorate-100652072","NCT07768982","Clinical Characteristics and Prognostic Factors in Patients With Meningitis at Sohag Governorate.","Analyze of Clinical Characteristics and Prognostic Factors in Patients With Meningitis at Sohag Governorate","Inclusion Criteria:\n\n* All patients diagnosed with meningitis admitted to Sohag Fever Hospital during the study period.\n* Patients of all age groups and both sexes.\n* Patients with confirmed diagnosis based on clinical features and CSF analysis.\n\nExclusion Criteria:\n\n* Patients with incomplete medical records.\n* Patients with uncertain diagnosis of meningitis.\n* Patients discharged against medical advice before completion of evaluation.",{"count":204,"type":19},300,"2 Weeks","analyze the clinical characteristics and prognostic factors in patients with meningitis at Sohag Governorate .This is an ambidirectional (retrospective and prospective), hospital-based observational study. The study involves a retrospective review of patient records over the past 3 years, combined with a prospective recruitment of new patients for one year from the initiation of the study",[208],"Meningitis",{"date":98,"type":42},{"date":211,"type":19},"2026-08-15",{"date":213,"type":19},"2027-11-15",{"name":48,"class":49},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100651982","cancer-ratio-and-cancer-ratio-plus-in-malignant-and-tuberculous-pleural-effusions-100651982","NCT07766876","Cancer Ratio and Cancer Ratio Plus in Malignant and Tuberculous Pleural Effusions","Role of Cancer Ratio and Cancer Ratio Plus in the Differentiation Between Malignant and Tuberculous Pleural Effusions .","CRPLUS-MPE-TPE","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Patients with Malignant or tuberculous pleural effusion\n* Availability of complete pleural fluid analysis including lymphocyte percentage ,pleural fluid ADA, and Serum LDH level\n\nExclusion Criteria:\n\n* Patients with mixed etiology effusions (e.g., malignancy with infection)\n* Prior pleural interventions affecting fluid analysis\n* Incomplete clinical or laboratory data",{"count":224,"type":19},120,"This prospective observational analytical study aims to assess the diagnostic value of Cancer Ratio and Cancer Ratio Plus in differentiating malignant pleural effusion from tuberculous pleural effusion. Adult patients with confirmed malignant or tuberculous pleural effusion will be recruited from the Chest Diseases Department, Sohag University Hospitals. Clinical, laboratory, and radiological data will be collected, and the diagnostic performance of both markers will be evaluated.",[227,228],"Malignant Pleural Effusion","Tuberculous Pleural Effusion",[230,231,232,233,234],"Cancer ratio","Cancer ratio plus","Serum LDH","Pleural fluid ADA","Pleural fluid analysis","2026-08-11",{"date":98,"type":42},{"date":238,"type":19},"2026-09-01",{"date":240,"type":19},"2027-08-31",{"name":48,"class":49},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":86,"minAge":59,"maxAge":179,"enrollmentInfo":249,"targetDuration":4,"studyType":114,"phases":251,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100651947","phase-1-second-trimester-abortion-with-letrozole-and-misoprostol-compared-to-misoprostol-alone-100651947","NCT07767435","Second Trimester Abortion With Letrozole and Misoprostol Compared to Misoprostol Alone","Termination of Second Trimester Abortion With Letrozole and Misoprostol Compared to Misoprostol Alone","Inclusion Criteria:\n\n* Pregnant women aged 18-45 years.\n* Failed pregnancy.\n* Gestational age between 14 and 20weeks, confirmed by ultrasonography on the day of admission.\n* Hemoglobin concentration \\>9 g\u002FdL.\n* Closed cervix.\n* Absence of products of conception in the cervical canal.\n\n  \\- Exclusion Criteria:\n* Previous attempt to terminate the current pregnancy.\n* Molar pregnancy (hydatidiform mole).\n* Pathological uterine lesions including uterine fibroids and congenital uterine malformations.\n* Cardiac disease.\n* Renal disease.\n* Hemorrhagic disorders.\n* Body mass index (BMI) \\>35 kg\u002Fm².\n* Documented hypersensitivity or allergy to letrozole, misoprostol, or any of the study medications.",{"count":250,"type":19},80,[252,253],"PHASE1","PHASE2","Termination of Second trimester Abortion with Letrozole and Misoprostol Compared to Misoprostol Alone",[256,257],"Abortion Induced Complicated","Abortion",[259,260],"medical abortion","induced abortion",{"date":98,"type":42},{"date":263,"type":19},"2026-08-01",{"date":265,"type":19},"2027-06-01",{"name":48,"class":49},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":273,"enrollmentInfo":274,"targetDuration":275,"studyType":21,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":50},"100651710","the-role-of-c-reactive-protein-crp-in-the-early-diagnosis-of-anastomotic-leakage-following-primary-repair-in-gastrointestinal-surgery-100651710","NCT07763379","THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERY","Inclusion Criteria:\n\n1. Adult patients aged 18 years or older.\n2. Patients having surgery for abdominal gastrointestinal disorders (esophageal- Gastric- small bowel -colon ) where a primary repair or anastomosis is performed such (pathological -traumatic )\n3. Patients fit for surgery\n4. Patients who provide informed written consent.\n\nExclusion Criteria:\n\n1- Patients younger than 18 years. 2. Patients with pre-existing systemic infection or sepsis outside GIT 3. Patients with liver cirrhosis affecting CRP synthesis. 4. Patients receiving corticosteroids or immunosuppressive therapy. 5. Patients refusing participation in the study 6. Post operative wound infection","70 Years",{"count":88,"type":19},"7 Days","Despite advancements in surgical procedures, Anastomotic leakage (AL) remains a common complication following gastrointestinal surgery. It carries a high rate of morbidity and mortality, increases the cost of treatment, and leads to further interventions and delayed recovery. As surgical practice advances, AL becomes a significant obstacle for gastrointestinal surgeons worldwide (Smith et al., 2023).\n\nThe rate of AL depends on the type of operation, the location of the anastomosis, the disease itself, the method of surgery, and patient-related factors. Patient factors that contribute to AL include malnutrition, diabetes mellitus, smoking, obesity, steroid use, emergency operations, and poor blood flow to tissues (Johnson and Lee, 2024).\n\nEven though AL begins with a small lesion in the area of the anastomosis, it can lead to extensive intra-abdominal sepsis, multiple organ failure, and death due to late diagnosis. Furthermore, in cases of oncological surgery, AL can negatively impact long-term outcomes because of delay in adjuvant treatment and increased recurrence (Brown et al., 2025).\n\nEarly identification of AL is quite challenging because postoperative symptoms are nonspecific and may resemble the common inflammatory reaction after major surgery. Symptoms including fever, tachycardia, abdominal pain, ileus, leukocytosis, or purulent drainage usually become visible only when the condition is already at an advanced stage. Radiologic tests including contrast-enhanced CT are effective methods in identifying complications. However, using these techniques in every patient after major surgery is neither feasible nor economical, and some early cases may be overlooked (Wilson et al., 2023).",[278],"Anastomosis, Leaking","2026-08-10",{"date":166,"type":42},{"date":235,"type":19},{"date":283,"type":19},"2027-01-12",{"name":48,"class":49},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":86,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":50},"100651170","updates-and-insights-on-her2-in-breast-cancer-in-sohag-governorate-100651170","NCT07758127","Updates and Insights on HER2 in Breast Cancer in Sohag Governorate","Updates and Insights on Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer in Sohag Governorate","HER2","Inclusion Criteria:\n\n* Breast cancer cases diagnosed during 2025 and 2026.\n* Cases with available HER2 immunohistochemical results.\n* Cases with sufficient tissue material for evaluation.\n* Cases with complete clinical and follow-up data.\n* Cases that were accessible for pathologic review\n\nExclusion Criteria:\n\n* Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.\n* Cases with incomplete clinical information.\n* Cases lacking adequate immunohistochemical assessment.\n* Cases outside the study period","26 Years","85 Years",{"count":181,"type":19},"* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.\n* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes\n* To access interobserval agreement in HER2 score interpretation",[298],"HER2 Status in Breast Cancer",[291],{"date":189,"type":42},{"date":302,"type":19},"2026-09",{"date":304,"type":19},"2027-12",{"name":48,"class":49},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":114,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":50},"100651684","reconstruction-of-first-web-space-after-trauma-and-burn-100651684","NCT07762404","Reconstruction of First Web Space After Trauma and Burn","Surgical Reconstruction of Post-Traumatic and Post-Burn First Web Space Obliteration: Functional and Aesthetic Outcome Analysis.","Inclusion Criteria:\n\n* Patients with post-burn or posttraumatic first web space contracture.Functional limitation of thumb abduction Patients medically fit for surgical intervention.\n\nExclusion Criteria:\n\n* Active infection in the affected hand. Uncontrolled diabetes or peripheral vascular disease Previous failed reconstruction of the same web spacel Patients unable to comply with postoperative follow-up.",{"count":314,"type":19},20,[116],"assess and compare the functional and aesthetic outcomes of different surgical techniques used for reconstruction of post-traumatic and post-burn first web space obliteration.",[318],"Reconstruction of First Web Space",[311],"2026-08-08",{"date":166,"type":42},{"date":323,"type":19},"2026-07-25",{"date":325,"type":19},"2027-07-15",{"name":48,"class":49},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":50},"100651207","comparison-between-non-contrast-magnetic-resonance-angiography-and-carotid-doppler-in-cerebrovascular-stroke-100651207","NCT07756775","Comparison Between Non-contrast Magnetic Resonance Angiography and Carotid Doppler in Cerebrovascular Stroke","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Clinically diagnosed ischemic stroke or transient ischemic attack (TIA).\n* Imaging performed within 7-14 days of symptom onset.\n* Hemodynamically stable and suitable for magnetic resonance imaging (MRI).\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke.\n* Previous carotid artery stenting.\n* Contraindications to MRI, including:\n\n  * Non-MRI-compatible pacemakers or other MRI-incompatible implants.\n  * Cochlear implants.\n  * MRI-incompatible metallic orthopedic implants.\n  * Severe claustrophobia.",{"count":334,"type":19},200,"This prospective observational study aims to compare the diagnostic performance of non-contrast magnetic resonance angiography (NC-MRA) and carotid Doppler ultrasonography in the evaluation of carotid artery disease among patients with ischemic cerebrovascular stroke or transient ischemic attack. A total of 200 adult patients presenting to Sohag University Hospital will undergo both imaging modalities. The study will assess the agreement between NC-MRA and carotid Doppler in detecting and grading carotid artery stenosis according to the NASCET criteria, with the goal of evaluating the clinical utility of each technique and optimizing imaging strategies for the assessment of cerebrovascular stroke.",[337,338,339],"Ischemic Stroke","Transient Ischemic Attack","Carotid Artery Stenosis (Symptomatic and Asymptomatic)","2026-08-07",{"date":235,"type":42},{"date":343,"type":42},"2026-07-20",{"date":345,"type":19},"2027-03-20",{"name":48,"class":49},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":86,"minAge":59,"maxAge":179,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":364,"locationsCount":4},"100651014","ultrasound-scoring-system-for-diagnosis-and-prediction-of-severity-and-surgical-outcomes-of-placenta-accreta-spectrum-100651014","NCT07755709","Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum","A Novel Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum","Inclusion Criteria:\n\n* Pregnant women aged 18 to 45 years.\n* Gestational age ≥28 weeks at the time of enrollment.\n* Diagnosed Placenta Previa with a history of:\n\n  * One or more previous cesarean sections\n  * Uterine scarring due to previous surgery as (myomectomy, D\\&C, Metroplasty).\n* Singleton pregnancy.\n\nExclusion Criteria:\n\n* Women with multiple pregnancies (twins, triplets, etc.).\n* Pregnancies complicated by acute medical conditions (e.g., heart failure, uncontrolled diabetes).\n* Prior history of Blood diseases. (other than those related to pregnancy).\n* Women who refuse to participate or withdraw consent during the study.",{"count":88,"type":19},"Primary Objective:\n\nTo determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta). To evaluate the diagnostic accuracy of the novel Ultrasound Scoring System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).\n\nSecondary Objective:\n\n* To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).\n* To assess the relationship between the novel ultrasound score and postoperative complications, such as:\n\n  * Requirement for hysterectomy\n  * Bladder or bowel injury\n  * Blood transfusion requirement\n  * ICU admission rates\n* To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.",[357],"Placenta Accreta, Third Trimester",[359],"placenta accreta","2026-08-04",{"date":279,"type":42},{"date":360,"type":19},{"date":265,"type":19},{"name":48,"class":49},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":4},"100649811","study-of-cd38-and-cd56-in-chronic-myeloid-leukemia-100649811","NCT07740603","Study of CD38 and CD56 in Chronic Myeloid Leukemia","Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia","Inclusion Criteria:\n\n* patients with chronic myeloid leukemia\n\nExclusion Criteria:\n\n* other hematological diseases",{"count":334,"type":19},"Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.\n\nThe aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.",[375],"Chronic Myeloid Leukemia (CML)",{"date":377,"type":42},"2026-08-05",{"date":238,"type":19},{"date":380,"type":19},"2027-07-01",{"name":48,"class":49},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":50},"100650693","breast-cancer-molecular-subtypes-and-skeletal-metastases-patterns-on-bone-scintigraphy-100650693","NCT07750340","Breast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone Scintigraphy","Association of Breast Cancer Molecular Subtypes With Patterns of Skeletal Metastases on Bone Scintigraphy","Inclusion Criteria:\n\n* Patients of both sexes (females and males) with a confirmed histopathological diagnosis of breast cancer, including all major histological types: Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), other mixed or less common epithelial variants.\n* Patient's age ranging from 18 to 80 years.\n* Available immunohistochemical (IHC) profiles from the primary breast tumor biopsy or surgery, covering all molecular subtypes including; Luminal A: (ER-positive, PR-positive, HER2-negative, and low Ki-67 index). Luminal B: (ER-positive, PR-variable, HER2-variable \"either positive or negative\", and high Ki-67 index). HER2-enriched: (ER-negative, PR-negative, and HER2-positive). Triple-Negative breast cancer (TNBC): (no ER, PR or HER2 expression).\n* Patients referred for bone scintigraphy as part of initial staging, follow-up, or due to clinical suspicion of bone metastasis.\n\nExclusion Criteria:\n\n* Patients with other primary malignancies (to avoid confusion regarding the origin of bone metastases).\n* Patients with incomplete medical records or unavailable immunohistochemical data.\n* Pregnant female patients.\n* Patients aged under 18 years old.","80 Years",{"count":181,"type":19},"The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy.\n\nThe study will include adult male and female patients aged 18 to 80 years with histopathologically confirmed breast cancer who are referred for whole-body bone scintigraphy.\n\nThe main questions it aims to answer are:\n\n* What is the frequency and pattern of skeletal metastases across different breast cancer molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Triple-Negative) on bone scintigraphy?\n* How do nuclear medicine scintigraphic findings correlate with tumor biomarker profiles? Researchers will compare imaging patterns among the different molecular subtype groups to determine if specific biomarker profiles correlate with distinct bone metastatic behaviors.",[393],"Breast Cancer",[395,396,397,398,393],"Bone Scintigraphy","Molecular Subtypes","Technetium Tc 99m MDP","Bone Metastases","2026-08-02",{"date":401,"type":42},"2026-08-06",{"date":44,"type":19},{"date":404,"type":19},"2027-09",{"name":48,"class":49},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":413,"conditions":414,"keywords":417,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":50},"100650580","study-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-adults-with-type-1-diabetes-100650580","NCT07750210","Study of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults With Type 1 Diabetes","Inclusion Criteria:\n\n1. age ≥ 18years,\n2. diagnosis of T1DM\n\nExclusion Criteria\n\n(1)Type 2 diabetes mellitus (2) using glucocorticoids (3) long-term alcohol consumption (4) previous diagnosis of other chronic liver diseases (viral, autoimmune, etc.), major diseases such as liver cirrhosis or tumors\n\n\\-",{"count":113,"type":19},"Type 1 diabetes (T1D) is a disease characterized by an absolute deficiency of insulin secondary to autoimmune destruction of pancreatic beta cells , historically individuals with T1D are not liable for metabolic complications.\n\nRecent evidence suggests a prevalence of MASLD in approximately 22.2% of adults with T1D; moreover, significant fibrosis (\\> F2) is observed 'in 13.2% and advanced fibrosis (\\> F3) in 5.12% of them (1) The development of MASLD is related to a persistence of inflammatory state and is favored by lipotoxicity due to the accumulation of free cholesterol(2) In individuals with T1D, MASLD risk may be influenced by disease-specific factors, including lifelong exposure to exogenous insulin, peripheral hyperinsulinemia with relative portal hypoinsulinemia, chronic hyperglycemia, marked glycemic variability, recurrent hypoglycemia, and progressive alterations in body composition. Even in the absence of classical insulin resistance, these factors may promote hepatic denovo lipogenesis, oxidative stress, and lipid accumulation through alternative metabolic pathways Type 1 diabetes (T1D) is a disease characterized by an absolute deficiency of insulin secondary to autoimmune destruction of pancreatic beta cells , historically individuals with T1D are not liable for metabolic complications.\n\nRecent evidence suggests a prevalence of MASLD in approximately 22.2% of adults with T1D; moreover, significant fibrosis (\\> F2) is observed 'in 13.2% and advanced fibrosis (\\> F3) in 5.12% of them (1) The development of MASLD is related to a persistence of inflammatory state and is favored by lipotoxicity due to the accumulation of free cholesterol(2) In individuals with T1D, MASLD risk may be influenced by disease-specific factors, including lifelong exposure to exogenous insulin, peripheral hyperinsulinemia with relative portal hypoinsulinemia, chronic hyperglycemia, marked glycemic variability, recurrent hypoglycemia, and progressive alterations in body composition. Even in the absence of classical insulin resistance, these factors may promote hepatic denovo lipogenesis, oxidative stress, and lipid accumulation through alternative metabolic pathways Type 1 diabetes (T1D) is a disease characterized by an absolute deficiency of insulin secondary to autoimmune destruction of pancreatic beta cells , historically individuals with T1D are not liable for metabolic complications.\n\nRecent evidence suggests a prevalence of MASLD in approximately 22.2% of adults with T1D; moreover, significant fibrosis (\\> F2) is observed 'in 13.2% and advanced fibrosis (\\> F3) in 5.12% of them (1) The development of MASLD is related to a persistence of inflammatory state and is favored by lipotoxicity due to the accumulation of free cholesterol(2) In individuals with T1D, MASLD risk may be influenced by disease-specific factors, including lifelong exposure to exogenous insulin, peripheral hyperinsulinemia with relative portal hypoinsulinemia, chronic hyperglycemia, marked glycemic variability, recurrent hypoglycemia, and progressive alterations in body composition. Even in the absence of classical insulin resistance, these factors may promote hepatic denovo lipogenesis, oxidative stress, and lipid accumulation through alternative metabolic pathways Type 1 diabetes (T1D) is a disease characterized by an absolute deficiency of insulin secondary to autoimmune destruction of pancreatic beta cells , historically individuals with T1D are not liable for metabolic complications.\n\nRecent evidence suggests a prevalence of MASLD in approximately 22.2% of adults with T1D; moreover, significant fibrosis (\\> F2) is observed 'in 13.2% and advanced fibrosis (\\> F3) in 5.12% of them (1) The development of MASLD is related to a persistence of inflammatory state and is favored by lipotoxicity due to the accumulation of free cholesterol(2) In individuals with T1D, MASLD risk may be influenced by disease-specific factors, including lifelong exposure to exogenous insulin, peripheral hyperinsulinemia with relative portal hypoinsulinemia, chronic hyperglycemia, marked glycemic variability, recurrent hypoglycemia, and progressive alterations in body composition. Even in the absence of classical insulin resistance, these factors may promote hepatic denovo lipogenesis, oxidative stress, and lipid accumulation through alternative metabolic pathways",[415,416],"MASLD","Type 1 Diabetes",[415,418],"TYPE 1 DIABETES",{"date":401,"type":42},{"date":421,"type":19},"2026-08-22",{"date":423,"type":19},"2028-08-22",{"name":48,"class":49},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":389,"enrollmentInfo":432,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":50},"100650398","assessment-of-retinal-microvascular-changes-by-oct-angiography-in-diabetic-retinopathy-100650398","NCT07747428","Assessment of Retinal Microvascular Changes by OCT Angiography in Diabetic Retinopathy","Assessment of Retinal Microvascular Changes by OCT Angiography and Their Correlation With Visual Acuity and Glycemic Control Across Different Stages of Diabetic Retinopathy","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Patients diagnosed with diabetic retinopathy.\n* Ability to undergo complete ophthalmic examination including OCT and OCT angiography.\n* Availability of HbA1c measurement within the study period.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous vitreoretinal surgery.\n* Significant media opacity affecting image quality (e.g., dense cataract or vitreous hemorrhage).\n* Other retinal vascular diseases (e.g., retinal vein occlusion).\n* Glaucoma or optic nerve diseases affecting visual function.\n* High myopia (\\>6 diopters).\n* Poor-quality OCTA images due to motion artifacts or poor fixation.\n* Refusal or inability to provide informed consent.\n\nExclusion Criteria:\n\n\\-",{"count":181,"type":19},"This observational cross-sectional study aims to assess retinal microvascular changes using optical coherence tomography angiography (OCTA) in patients with diabetic retinopathy. The study will evaluate retinal vessel density and foveal avascular zone parameters and investigate their correlation with best-corrected visual acuity and glycemic control (HbA1c) across different stages of diabetic retinopathy. The findings may improve understanding of retinal microvascular alterations and their clinical significance.",[435],"Diabetic Retinopathy",[437,438,439,435,440,441,442],"Optical Coherence Tomography Angiography","OCTA","Retinal Microvasculature","Visual Acuity","HbA1c","Vessel Density","2026-07-31",{"date":377,"type":42},{"date":446,"type":42},"2026-01-01",{"date":448,"type":19},"2026-12-31",{"name":48,"class":49},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":389,"enrollmentInfo":457,"targetDuration":4,"studyType":114,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":50},"100649763","factors-affecting-clinical-and-radiological-outcome-in-endovascular-management-of-acute-ischemic-stroke-due-to-large-vessel-occlusion-100649763","NCT07740018","Factors Affecting Clinical and Radiological Outcome in Endovascular Management of Acute Ischemic Stroke Due to Large Vessel Occlusion","FACTOR-LVO","Inclusion Criteria:\n\n* General Criteria (Applicable to All Time Windows)\n\n  * Age ≥ 18 to 80 years old.\n  * Acute ischemic stroke due to large vessel occlusion (LVO) presenting within 24 hours from symptom onset or last known well. Occlusion involving one of the following vessels:\n* internal carotid artery (ICA)\n* M1 segment of the middle cerebral artery (MCA)\n* A1 segment of the anterior cerebral artery (ACA)\n* P1 segment of the posterior cerebral artery (PCA)\n* Basilar artery (BA)\n* V4 segment of the vertebral artery (VA)\n\n  * National Institutes of Health Stroke Scale (NIHSS) score ≥ 6. Patients Presenting Within 0-6 Hours from Symptom Onset or Last Known Well ,\n  * Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6.\n\nPatients presenting 6-24 hours from the last known well, imaging eligibility based on :\n\n* Estimated ischemic core volume \\\u003C 70 mL.\n* Ratio of critically hypoperfused tissue to ischemic core (mismatch ratio) ≥ 1.8.\n* Absolute volume of potentially salvageable tissue (Diffusion to flair mismatch volume) ≥ 15 mL.\n\nExclusion Criteria:\n\n* • Patients with stroke resulting from etiologies other than LVO.\n\n  * Individuals with a history of previous strokes.\n  * Hemorrhagic stroke\n  * Large established infarction (e.g., ASPECTS \\\u003C 6 for patients within the early time window or imaging findings not meeting eligibility criteria in the late window).\n  * Patients presenting 6-24 hours from the last known well who do not meet advanced imaging selection criteria (e.g., DEFUSE 3 or DAWN eligibility criteria).\n  * Pre-stroke disability with a modified Rankin Scale (mRS) score ≥2.\n  * Rapid improvement in neurological status to an NIHSS \\\u003C 6 or evidence of vessel recanalization prior to randomization.",{"count":458,"type":19},40,[116],"Acute ischemic stroke (AIS), particularly if it is caused by a large-vessel occlusion (LVO), is a severe and life-threatening disease. Endovascular therapy (EVT) has rendered safe and effective treatment of AIS due to LVO possible, and new thrombolytic agents and neuroprotectants could soon complement pharmacological AIS therapy. These treatments are highly time dependent. Hence, the overarching goal in the management of patients with AIS is to rapidly and safely transfer, diagnose, and treat patients with AIS (1).\n\nThe only available 2 treatment options are intravenous alteplase and endovascular therapy (mechanical clot removal), both of which are highly time dependent. Thus, rapid patient transfer, diagnosis, and treatment are crucial, and time-consuming imaging methods and overly selective treatment selection criteria should be avoided (2).\n\nImaging is crucial for AIS management, as it confirms the diagnosis and guides treatment, with intravenous tissue plasminogen activator (alteplase) and\u002For EVT, the 2 evidence-based treatment strategies for AIS. Every 30-min delay in recanalization decreases the chance of a good functional outcome by 8% to 14% (3).\n\nClinical outcome after large-vessel occlusive strokes depends on admitting clinical condition, successful recanalization, and robust collateral circulation. However, predicting successful recanalization and quantifying collateral status in the acute setting remain elusive (4).\n\nSuccessful recanalization has many predictive factors. Strong evidence supports increasing clot length being associated with poor recanalization. Current imaging techniques completed in the acute setting suggest that clot length can be estimated with a clot burden score (5).\n\nStudies consistently show that independent predictors in clinical outcome remain the patient's admission clinical condition as evaluated by baseline NIH Stroke Scale (NIHSS) scores and ischemic lesion volume. Emphasis on lesion volume suggested that stroke mechanism, particularly lacunar strokes with their smaller ischemic volumes, could be an independent predictor for favorable clinical outcome. However, predicting clinical outcome with stroke mechanism, particularly in large vessel occlusions (LVO), remains elusive (6).\n\nAs thrombus origin site (i.e., vein, artery, or heart) is thought to play a role in clot composition, cardioembolic and paradoxical strokes with their greater fibrin content and red cells were thought to be more susceptible to fibrinolysis than heterogeneous, chronic thrombotic arterial plaques formed in artery-to-artery strokes. However, studies continue to show that stroke mechanism does not influence recanalization or clinical outcome after intravenous rt-PA (IVtPA) (7).\n\nRadiological signs that are readily available on a patient's index CT scan have generated interest as predictors for patients undergoing EVT for LVO AIS. For example, poor baseline collateral flow status and Alberta Stroke Program Early CT Score (ASPECTS), assessed via CT angiography, are associated with a larger ischemic core and worse functional outcomes. Other radiological variables which have been investigated include clot characteristics including clot length, density, surface phenotype, truncal versus branch-type occlusions and the presence of a meniscus sign. Further radiological variables that have been studied pertain to vascular anatomy and include parameters that quantify vascular tortuosity such as the aortic arch type (8).\n\nDespite advances in the management of acute ischemic stroke due to large-vessel occlusion, significant variability still exists in both clinical and radiological outcomes among patients. Moreover, the relative contribution and interaction of different clinical and imaging predictors in determining treatment success and functional recovery remain not fully established. In addition, there is still no complete consensus regarding the most reliable predictors of recanalization and favorable outcomes in the acute setting, particularly in relation to thrombus characteristics, collateral status, and vascular anatomy (9).\n\nTherefore, this study aims to evaluate factors affecting clinical and radiological outcome in management of acute ischemic stroke due to large vessel occlusion.",[462],"Endovascular Thrombectomy",{"date":443,"type":42},{"date":263,"type":19},{"date":466,"type":19},"2028-08-01",{"name":48,"class":49},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":86,"minAge":476,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":114,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":50},"100649485","endovascular-management-of-pelvic-congestion-syndrome-100649485","NCT07735156","Endovascular Management of Pelvic Congestion Syndrome","Role of Endovascular Management of Pelvic Congestion Syndome","PCSIR","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Chronic pelvic pain for more than 6 months.\n* Clinical suspicion of pelvic congestion syndrome.\n* Imaging findings consistent with pelvic congestion syndrome on Doppler ultrasound, CT venography, MR venography, or catheter venography.\n* Patients willing to undergo endovascular embolization.\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Pregnancy.\n* Active pelvic inflammatory disease.\n* Known pelvic malignancy.\n* Chronic pelvic pain due to other identifiable causes (e.g., endometriosis, large uterine fibroids).\n* Contraindication to iodinated contrast media.\n* Severe renal impairment.\n* Uncorrectable coagulation disorders.\n* Refusal to participate.","17 Years","55 Years",{"count":18,"type":19},[116],"Pelvic congestion syndrome (PCS) is a common cause of chronic pelvic pain in women and is associated with pelvic venous insufficiency. This prospective interventional study aims to evaluate the safety and clinical effectiveness of endovascular embolization in relieving symptoms and improving quality of life in women diagnosed with PCS",[482],"Pelvic Congestion Syndrome","2026-07-26",{"date":485,"type":42},"2026-07-29",{"date":487,"type":42},"2026-01-14",{"date":489,"type":19},"2027-06-20",{"name":48,"class":49},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":114,"phases":499,"briefSummary":500,"conditions":501,"keywords":504,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":516,"locationsCount":4},"100649133","evaluation-of-the-outcome-of-septoplasty-with-or-without-inferior-turbinate-reduction-100649133","NCT07731152","Evaluation of the Outcome of Septoplasty With or Without Inferior Turbinate Reduction","Inclusion Criteria:\n\n* Patients with symptomatic deviated nasal septum causing persistent nasal obstruction, aged 18-50 years, who failed medical treatment for at least 3 months, will be included in the study.\n\nExclusion Criteria:\n\n* Patients with previous nasal surgery, nasal polyposis, chronic rhinosinusitis, alar collapse, uncontrolled allergic rhinitis, nasal tumors, or external nasal deformity requiring rhinoplasty will be excluded from the study.","50 Years",{"count":458,"type":19},[116],"This prospective comparative study aims to evaluate the outcomes of septoplasty with or without inferior turbinate reduction in patients with symptomatic deviated nasal septum. Subjective and objective outcomes will be assessed using the NOSE score, Peak Nasal Inspiratory Flow (PNIF), and nasal endoscopic examination before and after surgery.",[502,503],"Deviated Nasal Septum","Nasal Obstruction Septal Deviation Compensatory Inferior Turbinate Hypertrophy",[505,506,507,508,509,510,511],"septoplasty","deviated nasal septum","nasal obstruction","inferior turbinate hypertrophy","nose score","peak nasal inspiratory flowmeter (PNIF)","endoscopic assessment","2026-07-23",{"date":128,"type":42},{"date":302,"type":19},{"date":404,"type":19},{"name":48,"class":49},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":273,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":50},"100649211","reliability-of-optical-and-ultrasound-biometry-in-silicon-filled-eyes-100649211","NCT07731984","Reliability of Optical and Ultrasound Biometry in Silicon Filled Eyes","Inclusion Criteria:\n\n* patients with clinical diagnosis of retinal detachment (RD)\n* planned for pars plana vitrectomy with silicon oil tamponade\n\nExclusion Criteria:\n\n* previous intraocular surgery\n* failed optical biometry acquisition\n* recurrent RD\n* combined scleral buckle surgery",{"count":181,"type":19},"Optical and ultrasound biometry will be done for Patients who will undergo pars plana vitrectomy (PPV) and silicon oil injection preoperative and post operative 1 month",[526],"Retinal Detachment","2026-07-22",{"date":128,"type":42},{"date":530,"type":42},"2026-05-30",{"date":532,"type":19},"2026-10-30",{"name":48,"class":49},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":541,"targetDuration":542,"studyType":21,"phases":4,"briefSummary":543,"conditions":544,"keywords":547,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100648791","relation-between-glycemic-control-and-retinal-microvascular-changes-in-diabetic-patients-using-octa-100648791","NCT07726381","Relation Between Glycemic Control and Retinal Microvascular Changes in Diabetic Patients Using OCTA","Retinopathy","Inclusion Criteria:\n\n* Diabetic patients with diabetic retinopathy with controlled and uncontrolled HbA1c\n\nExclusion Criteria:\n\n* Media opacities affecting OCT imaging (corneal pathologies, dense cataracts, vitreous opacities, etc).\n* Patients with any other retinal vascular diseases (retinal vein occlusion, central serrous chorioretinopathy, age-related macular degeneration, etc).\n* Patients who have had previous intravitreal injections or Laser treatment.\n* Patients who underwent previous vitreoretinal surgeries.\n* Patients with recent history of undergoing cataract surgery.\n* Patients with uncontrolled glaucoma or ocular inflammations (eg: vitritis).",{"count":88,"type":19},"1 Year","An observational cross-sectional comparative study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt to detect the relation between glycemic control and retinal microvascular changes in diabetic patients using OCTA",[545,546],"Diabetic Retinopathy (DR)","Retinal Microvascular Changes",[548,549,550],"retinal microvascular changes","diabetic retinopathy","Optical coherence topography",{"date":552,"type":42},"2026-07-24",{"date":263,"type":19},{"date":555,"type":19},"2027-02-01",{"name":48,"class":49},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":16,"minAge":59,"maxAge":160,"enrollmentInfo":564,"targetDuration":4,"studyType":114,"phases":566,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":50},"100648322","efficacy-of-adding-intrathecal-morphine-to-erector-spinae-plane-block-for-postoperative-analgesia-after-midline-laparotomy-100648322","NCT07720739","Efficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy","Efficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy: A Prospective Randomized Study","Inclusion Criteria Patients scheduled to undergo elective or emergency midline exploratory laparotomy.\n\nAmerican Society of Anesthesiologists (ASA) physical status I, II, or III. Intact cognitive ability to comprehend study procedures, use the Numeric Rating Scale (NRS) accurately, and provide informed consent.\n\nExclusion Criteria Contraindications to regional or neuraxial anesthesia (e.g., patient refusal, localized infection at needle insertion sites, known coagulopathy (INR \\>1.5 or platelet count \\\u003C80,000\u002F\\\\mu L), or un-pausable therapeutic anticoagulation).\n\nKnown allergy or severe hypersensitivity to local anesthetics or morphine. Chronic pain conditions requiring daily opioid consumption for \\>3 months preoperatively.\n\nDocumented history of substance use disorder. Severe chronic respiratory disease (e.g., COPD requiring home oxygen therapy, or severe obstructive sleep apnea not managed with CPAP).\n\nNeurological or psychiatric conditions that compromise sensory perception or communication.\n\nSurgical incisions planned to extend significantly past the midline. Severe spinal deformities or a history of spinal surgery at the targeted block\u002Finjection interspaces.\n\nConcurrent enrollment in any other interventional clinical trial.",{"count":565,"type":19},75,[116],"This study evaluates whether combining two distinct pain-relief techniques-a peripheral nerve block called the Erector Spinae Plane Block (ESPB) and a low-dose spinal medication injection called Intrathecal Morphine (ITM)-provides better postoperative pain management for adult patients undergoing major midline abdominal surgery (laparotomy) compared to using either technique alone. The main goal is to see if this combination improves pain control and reduces the total amount of opioids required by patients within the first 48 hours after surgery.",[569,570],"Postoperative Pain","Midline Laparotomy",[572,573,574,575],"Erector Spinae Plane Block","Intrathecal morphine","Opioid-sparing","Abdominal surgery","2026-07-19",{"date":527,"type":42},{"date":579,"type":19},"2026-07",{"date":581,"type":19},"2026-12",{"name":48,"class":49},""]